Anti-aging research, supplements, and the science of living longer.
The longevity biotech sector saw significant movement this week with Genentech acquiring Alector’s AL050 for $100M upfront and Tiny Health securing a $33M funding round for gut microbiome analysis. Additionally, cellular rejuvenation therapies have entered human trials, and EU longevity strategies are gaining political momentum.
The FDA has formally placed aging and longevity medicine on its regulatory science agenda for 2027, signaling major institutional backing for anti-aging interventions. Meanwhile, clinical evidence continues to tighten around rapamycin's immune-enhancing effects at low doses, and NAD+ precursors (NMN/NR) have confirmed NAD level doubling in humans within 14 days. Industry momentum remains strong, with the longevity biotech sector continuing to attract major capital despite broader biotech headwinds.
This week's longevity news centers on translational geroscience — human trial data finally challenging the mouse-model era — and a provocative mouse study showing GLP-1 drugs (Ozempic) extended lifespan in aged rodents. Industry momentum continues with record funding levels and major coverage of Oura's IPO from Longevity.Technology's Week 39 roundup. Rapamycin commentary remains prominent, with new analysis of its evidence and limits.
This week's standout is a regenerative medicine twist on rapamycin: nanoparticle delivery that rejuvenates aging spinal discs. On the industry side, Longevity.Technology published its biotech market report framing a $617 billion market by 2045, while CNBC reports record 2025 investment of $18.4 billion flowing into longevity biotech. Meanwhile, a new podcast conversation with Dr. David Barzilai cuts through hype on what actually slows biological aging.
This week, the longevity sector saw a massive surge in capital, with global investment surpassing $30 billion as new reports predict clinical longevity drugs by 2035. In research news, a new benchmark revealed that compact AI models outperform frontier systems in aging biology, while industry experts clarified that current evidence still heavily favors lifestyle interventions over unproven supplements.
Semaglutide (Ozempic) has been shown to slow biological aging and extend lifespan in healthy older mice, suggesting GLP-1 drugs may activate longevity pathways independent of weight loss. Meanwhile, the longevity biotech sector continues to attract significant capital, with recent developments including Moonwalk's $70M raise for RNAi therapies and Science Corp's $230M funding for vision restoration.
This week, a new study published in *Nature Biotechnology* validated the use of proteomic aging clocks to assess geroprotective effects in a Phase 2a clinical trial. In the industry sector, Moonwalk Therapeutics secured $70 million in Series B funding for adipose-targeted RNAi, while GlycanAge expanded its aging science operations into Japan.
The first major clinical trial of an AI-generated longevity drug, rentosertib, has yielded early positive data on biological aging markers. Meanwhile, the industry is shifting toward defined disease endpoints rather than broad "anti-aging" claims, and major biotech players like Celularity and Daewoong are securing significant manufacturing deals and patents to accelerate their pipelines.
This week’s longevity landscape is defined by a critical reality check on rapamycin, with new data suggesting limited evidence for longevity benefits in healthy adults. Meanwhile, the industry sector is heating up with major funding rounds, including an $820M raise for Veradermics and a $50M launch for biological AI firm Network Bio. Emerging research also highlights the potential of xenotransplantation to extend healthspan, alongside new AI-driven approaches to drug repurposing.
This week's longevity landscape is dominated by a critical re-evaluation of rapamycin's efficacy in healthy adults, with new data suggesting limited benefits for lifespan extension. Meanwhile, the industry sector shows robust growth, with market research projecting a 12.9% CAGR for epigenetic reprogramming through 2030, and clinical trials continue to explore the intersection of senolytics and metabolic health.
This week's longevity science updates are dominated by a comprehensive review of rapamycin's clinical evidence, highlighting its potential to mimic caloric restriction in humans. Additionally, recent industry reports emphasize the rapid growth of cellular reprogramming therapies, with the market projected to expand significantly through 2026.
The longevity sector saw a surge in biotech developments this week, headlined by Generation Lab’s controversial claim of a "rejuvenation treatment" for blood, alongside significant clinical trial updates from Altimmune and BTT targeting metabolic and neurodegenerative conditions. Additionally, researchers at NYU and Function Health are advancing early disease detection protocols, while Mount Sinai launches a major prize initiative focused on immune system resetting.
The past 24 hours in longevity science were marked by a major new study in *Nature Medicine* analyzing how epigenetic clocks respond to various anti-aging interventions, alongside fresh industry moves including Altimmune entering Phase 3 trials for a dual-hormone therapy. Additionally, the XPRIZE Healthspan competition announced its top 10 finalists, highlighting the accelerating pace of healthspan-focused innovation.
The longevity sector is experiencing a surge in AI-driven discovery and novel pharmacological interventions, highlighted by Network Bio’s $50 million launch for biological AI and Enveda’s "exercise pill" that bypasses physical activity. Simultaneously, regulatory scrutiny is tightening around biological age clocks, with experts arguing they are "tools, not verdicts," while XellSmart secures FDA fast-track designation for its Parkinson’s cell therapy.
This week's longevity research highlights the mixed evidence around rapamycin's human efficacy, emerging data on senescent cell markers in clinical trials, and continued strong biotech funding in the anti-aging space. While animal studies show promising lifespan extensions, human clinical evidence remains limited and cautious.
This week brings clinical validation for low-dose rapamycin's effects on aging biomarkers, emerging evidence on senolytics as a therapeutic frontier, and major funding momentum in longevity biotech. A meta-analysis confirms rapamycin rivals dietary restriction for lifespan extension, while industry capital continues flowing toward cellular rejuvenation and age-reversal technologies.
A landmark human trial reveals rapamycin's geroprotective effects through reduced cellular senescence in aging immune cells, while new research on immune system rejuvenation kicks off this month. Industry momentum accelerates with major biotech partnerships targeting Alzheimer's and neurodegenerative diseases, alongside emerging evidence on laser therapy for reversing skin aging markers.
Northeastern researchers revealed a new approach to identifying existing drugs that could impact aging by analyzing aging-related genes, while a fresh study from USC linked low-protein diets supplemented with amino acids to extended healthspan in mice. Meanwhile, a Boston biotech company has dosed the first human with a cellular reprogramming drug—marking a watershed moment in longevity intervention trials.
Cell reprogramming emerges as the dominant approach in longevity science following Life Biosciences' first human treatment injection for glaucoma. Meanwhile, rapamycin shows promise in clinical trials for muscle and bone health, while industry funding for reverse-aging startups accelerates with NewLimit's $435 million Series C round.
Cellular reprogramming moves from bench to bedside as Life Biosciences doses the first human with a vision-restoration therapy, while longevity biotech attracts record investment—NewLimit raises $435M at $3.1B valuation. Rapamycin shows promise for muscle and bone health in clinical trials, though recent analyses reveal limitations for healthy adults seeking lifespan extension.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
